医学
血脑屏障
缓激肽
神经科学
中枢神经系统
生物信息学
重症监护医学
药理学
内科学
生物
受体
作者
Robert A. KrolI,Edward A. Neuwelt,Edward A. Neuwelt
出处
期刊:Neurosurgery
[Oxford University Press]
日期:1998-05-01
卷期号:42 (5): 1083-1099
被引量:574
标识
DOI:10.1097/00006123-199805000-00082
摘要
OBJECTIVE: This article reviews historical aspects of the blood-brain barrier (BBB) and recent advances in mechanisms to deliver therapeutic agents across the BBB for the treatment of intracerebral tumors and other neurological diseases. METHODS: The development of the osmotic BBB disruption procedure as a clinically useful technique is described. Osmotic BBB disruption is contrasted with alternative methods for opening or bypassing the BBB, including pharmacological modification of the BBB with bradykinin and direct intracerebral infusion. RESULTS: Laboratory studies have played a fundamental role in advancing our understanding of the BBB and delivery of agents to brain. Preclinical animal studies will continue to serve an integral function in our efforts to improve the diagnosis and treatment of a number of neurological disorders. Techniques involving the modification of the BBB and/or blood-tumor barrier to increase delivery of therapeutic agents have been advanced to clinical trials in patients with brain tumors with very favorable results. CONCLUSION: Improving delivery of agents to the brain will play a major role in the therapeutic outcome of brain neoplasms. As techniques for gene therapy are advanced, manipulation of the BBB also may be important in the treatment of central nervous system genetic disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI